Outcomes Following Depot Gonadotropin-Releasing Hormone Agonist Treatment in Children with Central Precocious Puberty: A Retrospective Analysis

Gonadotropin-releasing hormone agonist (GnRHa) therapy is widely endorsed for Central Precocious Puberty (CPP). This longitudinal observational study aimed to assess the influence of GnRHa on anthropometric measures over a decade. Pre- and post-treatment clinical records of 196 patients (7 boys, 189 girls) who received GnRHa therapy were reviewed. The study showed that in girls, post-treatment final height exceeded pre-treatment predicted adult height (p < 0.001). BMI-SDS notably increased in treated girls (p < 0.001) contrasting with boys. GVI declined during therapy (p < 0.001) but rebounded post-therapy (p < 0.05), without reaching pre-treatment levels. Additionally, 43.7% of girls reported menarche 1.1 ± 0.7 years after therapy, but 50% experienced irregular cycles. Conclusion: GnRHa has positive effect on final height.